Medical Knowledge Sharing

Apparatus

Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

Medical

Standard Chemotherapy + Mitazalimab, More Than 90% Effective In The Treatment Of Pancreatic Cancer!

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Apparatus

Fda Accepts Zuranolone's Nda Application And Grants It Priority Review For The Treatment Of Mdd And Pdd

Approval for new FIC depression drug on the horizon!